SCHEMBL24414766

SCHEMBL24414766

CC(C)(NC(=O)c1ccc(Cl)s1)C(=O)Nc1ccc(Br)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.67
F10 P00742 4/20 0.65
NPC1 O15118 8/20 0.48
RAB9A P51151 8/20 0.48
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
KDM4E B2RXH2 5/20 0.43
NPSR1 Q6W5P4 2/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RXFP1 Q9HBX9 2/20 0.41
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
HPGD P15428 2/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24414733 0.90 AR (0.70) ARF10NPC1RAB9AMEN1
SCHEMBL24414750 0.87 AR (0.67) ARF10NPC1RAB9AMEN1
SCHEMBL24414748 0.81 AR (1.00) ARF10NPC1RAB9AMEN1
SCHEMBL6460829 0.79 F10 (0.68) ARF10NPC1RAB9AMEN1
SCHEMBL6459985 0.79 F10 (1.00) ARF10MEN1KMT2AHTT
SCHEMBL3426150 0.79 F10 (0.73) ARF10NPC1RAB9AMEN1
SCHEMBL3424489 0.77 F10 (0.81) ARF10NPC1RAB9AMEN1
SCHEMBL2570856 0.76 AR (0.62) ARF10NPC1RAB9AMEN1
SCHEMBL3034870 0.76 AR (0.62) ARF10NPC1RAB9AMEN1
SCHEMBL6454606 0.76 F10 (0.63) ARF10NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691960-B2 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-07-04 US disclosed
WO-2022096542-A1 2-[THIOPHEN-2-YL)FORMAMIDO]-N-(PHENYL)-2-METHYLPROPANAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-12 WO disclosed
US-20220144796-A1 2-[Thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use therof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691960-B2 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament IDO1, IDO2, INMT AR 2770/4885F10 4273/4885NPC1 2714/4885
US-20220144796-A1 2-[Thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use therof as medicament IDO1, IDO2, TPH1 AR 2457/4885F10 3905/4885NPC1 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.